The number of new graduates hired for sales rep roles increased in FY2025 after declining for five consecutive years, a…
BUSINESS
Drug Makers Terminate Lysozyme, Pronase Sale after MHLW Panel Finds Them Ineffective
Drug makers marketing enzyme preparations that contain lysozyme or pronase said on March 17 that they have decided to discontinue the sale of the products and started their voluntary recalls after a health ministry panel dismissed their efficacy earlier in…
To read the full story
Related Article
- Panel Finalizes “No Efficacy” Decision for Lysozyme, Pronase; MHLW Issues Notifications for Ethical, OTC Products
March 28, 2016
- Approvals for 3 Dasen-Like Drugs to Be Withdrawn
July 11, 2011
- Takeda to Voluntarily Recall Dasen
February 28, 2011
- Quick Answer Required on Efficacy of Dasen
February 14, 2011
- Dasen to Be Re-designated for Reevaluation
January 31, 2011
BUSINESS
- Takeda on Course to Stable Growth as Late-Stage Assets Near Market
May 9, 2025
- Lilly Japan Scores Double-Digit Growth for 2nd Year as Mounjaro Delivers
May 9, 2025
- Ono’s Profits Slide Over 60% as Deciphera Buyout Costs Swell
May 9, 2025
- Kyowa Kirin Announces Another Buyout Package; Job Cut Target Not Set
May 8, 2025
- Pfizer Seeks Wider Label for PARP Inhibitor Talzenna in Japan
May 8, 2025
The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…